Baseline Elevations of Leukotriene Metabolites and Altered Plasmalogens Are Prognostic Biomarkers of Plaque Progression in Systemic Lupus Erythematosus

• Published in: Frontiers in cardiovascular medicine 2022-05, Vol.9, p.861724-861724
• Main Authors: Baig, Sahar, Vanarsa, Kamala, Ding, Huihua, Titus, Anto Sam Crosslee Louis Sam, McMahon, Maureen, Mohan, Chandra
• Format: Article
• Language: English
• Subjects: atherosclerosis; biomarkers; blood; Cardiovascular Medicine; lupus; metabolites
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2022.861724

Systemic lupus erythematosus (SLE) is associated with an increased incidence of acute and chronic cardiovascular disease as compared to the general population. This study uses a comprehensive metabolomic screen of baseline sera from lupus patients to identify metabolites that predict future carotid plaque progression, following 8-9 years of follow-up. Nine patients had SLE without plaque progression, 8 had SLE and went on to develop atherosclerotic plaques (SLE ), and 8 patients were controls who did not have SLE. The arachidonic acid pathway metabolites, leukotriene B4 (LTB4) and 5-hydroxyeicosatetraenoic acid (5-HETE), and the oxidized lipids 9/13-hydroxyoctodecadienoic acid (HODE) were found to be significantly altered ( < 0.05 and fold-change >2) in SLE patients compared to SLE patients without plaque progression. SLE patients also exhibited significantly altered levels of branched chain amino acid (BCAA) metabolites and plasmalogens compared to the non-SLE controls. Taken together with the rich literature on these metabolites, these findings suggest that the identified metabolites may not only be prognostic of cardiovascular disease development in SLE patients, but they may also be active drivers of atheroma formation. Early identification of these high risk SLE patients may help institute preventive measures early in the disease course.